Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and cdc2-
like kinases (CLK1-4) belong to the CMGC group of serine/threonine kinases. These protein …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) play a large variety of cellular functions and are involved in several diseases …

Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Currently, heterocycles have occupied an important position in the fields of drug design.
Among them, azaindole moiety is regarded as one privileged scaffold to develop therapeutic …

Protein kinases represent a very pharmacologically attractive class of targets; however,
some members of the family still remain rather unexplored. The biology and therapeutic …

Covering 1972 to 2021 Malaria remains a significant public health problem in some regions
of the world. The great efforts to control malaria have been severely compromised due to the …

Modern drug design aims to discover novel lead compounds with attractable chemical
profiles to enable further exploration of the intersection of chemical space and biological …

A major advance in antimalarial drug discovery has been the shift towards cell-based
phenotypic screening, with notable progress in the screening of compounds against the …